Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer
Caribou Biosciences (Nasdaq: CRBU) has appointed Sri Ryali as Chief Financial Officer, effective immediately. Ryali brings 20 years of finance and commercial experience in the biopharmaceutical industry and will lead corporate finance, investor relations, and corporate communications functions, reporting to CEO Rachel Haurwitz.
Ryali previously served as CFO of Codexis and Eiger BioPharmaceuticals, and held senior finance positions at Aimmune Therapeutics, Onyx Pharmaceuticals, and Amgen. He holds an MBA from UCLA Anderson School of Management and a BA in economics and microbiology from UCLA.
The appointment comes at a important time as Caribou advances four clinical-stage programs for hematologic malignancies and autoimmune diseases, with multiple datasets expected to be disclosed in 2025. The company focuses on developing off-the-shelf CAR-T cell therapies using CRISPR genome-editing technology.
Caribou Biosciences (Nasdaq: CRBU) ha nominato Sri Ryali come Chief Financial Officer, con effetto immediato. Ryali porta con sé 20 anni di esperienza finanziaria e commerciale nel settore biofarmaceutico e guiderà le funzioni di finanza aziendale, relazioni con gli investitori e comunicazioni aziendali, riportando al CEO Rachel Haurwitz.
In precedenza, Ryali ha ricoperto il ruolo di CFO presso Codexis e Eiger BioPharmaceuticals, e ha occupato posizioni di alto livello nella finanza presso Aimmune Therapeutics, Onyx Pharmaceuticals e Amgen. Ha conseguito un MBA presso la UCLA Anderson School of Management e una laurea in economia e microbiologia presso UCLA.
Questa nomina arriva in un momento importante poiché Caribou avanza con quattro programmi clinici per neoplasie ematologiche e malattie autoimmuni, con più set di dati previsti per essere divulgati nel 2025. L'azienda si concentra sullo sviluppo di terapie CAR-T pronte all'uso utilizzando la tecnologia di editing genetico CRISPR.
Caribou Biosciences (Nasdaq: CRBU) ha nombrado a Sri Ryali como Director Financiero, con efecto inmediato. Ryali aporta 20 años de experiencia en finanzas y comercio en la industria biofarmacéutica y liderará las funciones de finanzas corporativas, relaciones con inversores y comunicaciones, reportando a la CEO Rachel Haurwitz.
Anteriormente, Ryali fue CFO de Codexis y Eiger BioPharmaceuticals, y ocupó cargos de finanzas senior en Aimmune Therapeutics, Onyx Pharmaceuticals y Amgen. Tiene un MBA de la UCLA Anderson School of Management y una licenciatura en economía y microbiología de UCLA.
Este nombramiento se produce en un momento importante, ya que Caribou avanza en cuatro programas clínicos para malignidades hematológicas y enfermedades autoinmunes, con múltiples conjuntos de datos que se espera sean revelados en 2025. La compañía se centra en desarrollar terapias CAR-T listas para usar utilizando la tecnología de edición genética CRISPR.
Caribou Biosciences (Nasdaq: CRBU)가 Sri Ryali를 최고 재무 책임자로 즉시 임명했습니다. Ryali는 생물 제약 산업에서 20년의 재무 및 상업 경험을 가지고 있으며, 기업 재무, 투자자 관계 및 기업 커뮤니케이션 기능을 이끌고, CEO Rachel Haurwitz에게 보고하게 됩니다.
이전에는 Codexis 및 Eiger BioPharmaceuticals의 CFO로 재직했으며, Aimmune Therapeutics, Onyx Pharmaceuticals 및 Amgen에서 고위 재무 직책을 역임했습니다. UCLA Anderson School of Management에서 MBA를 취득했으며, UCLA에서 경제학과 미생물학으로 학사학위를 받았습니다.
이번 임명은 Caribou가 혈액 악성 종양 및 자가 면역 질환을 위한 네 가지 임상 프로그램을 진행하고 있으며, 2025년에 여러 데이터 세트를 공개할 예정인 중요한 시점에서 이루어졌습니다. 이 회사는 CRISPR 유전자 편집 기술을 사용하여 즉시 사용할 수 있는 CAR-T 세포 치료제를 개발하는 데 집중하고 있습니다.
Caribou Biosciences (Nasdaq: CRBU) a nommé Sri Ryali au poste de directeur financier, avec effet immédiat. Ryali apporte 20 ans d'expérience en finance et en commerce dans l'industrie bio-pharmaceutique et dirigera les fonctions de finance d'entreprise, de relations investisseurs et de communications, reportant à la CEO Rachel Haurwitz.
Auparavant, Ryali était CFO de Codexis et Eiger BioPharmaceuticals et a occupé des postes financiers senior chez Aimmune Therapeutics, Onyx Pharmaceuticals et Amgen. Il détient un MBA de la UCLA Anderson School of Management et un diplôme en économie et microbiologie de UCLA.
Cette nomination intervient à un moment important, alors que Caribou avance quatre programmes cliniques pour des maladies hématologiques et auto-immunes, avec de multiples ensembles de données attendues pour être divulguées en 2025. L'entreprise se concentre sur le développement de thérapies CAR-T prêtes à l'emploi utilisant la technologie d'édition génétique CRISPR.
Caribou Biosciences (Nasdaq: CRBU) hat Sri Ryali mit sofortiger Wirkung zum Chief Financial Officer ernannt. Ryali bringt 20 Jahre Erfahrung in Finanz- und Geschäftstätigkeiten in der biopharmazeutischen Industrie mit und wird die Funktionen Unternehmensfinanzen, Investor Relations und Unternehmenskommunikation leiten, wobei er an die CEO Rachel Haurwitz berichtet.
Vorher war Ryali CFO von Codexis und Eiger BioPharmaceuticals und hatte führende Finanzpositionen bei Aimmune Therapeutics, Onyx Pharmaceuticals und Amgen inne. Er hat einen MBA von der UCLA Anderson School of Management sowie einen Bachelorabschluss in Wirtschaft und Mikrobiologie von UCLA.
Die Ernennung erfolgt zu einem wichtigen Zeitpunkt, da Caribou vier klinische Programme für hämatologische Malignome und autoimmune Erkrankungen vorantreibt, wobei mehrere Datensätze für 2025 erwartet werden. Das Unternehmen konzentriert sich auf die Entwicklung von sofort verwendbaren CAR-T-Zelltherapien unter Verwendung der CRISPR-Gentechnologie.
- Company has four clinical-stage programs in development
- Multiple dataset disclosures planned for 2025
- New CFO brings extensive experience from major biopharmaceutical companies
- None.
BERKELEY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sri Ryali as chief financial officer, effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in the biopharmaceutical industry to his role, and he will be responsible for the strategic leadership of the corporate finance, investor relations, and corporate communications functions. He will report to Rachel Haurwitz, PhD, Caribou’s president and chief executive officer.
“I am excited to welcome Sri to Caribou at the beginning of this pivotal year for our organization as we advance four clinical-stage programs for hematologic malignancies and autoimmune diseases and plan to disclose multiple datasets in 2025,” said Dr. Haurwitz. “Sri’s leadership experience at biopharmaceutical companies across all stages of drug development and commercialization will be valuable as we execute on our plans and prepare for the next steps for our programs.”
Most recently, Mr. Ryali served as the chief financial officer of Codexis, Inc., a publicly traded enzyme engineering company. Previously, he served as chief financial officer of Eiger BioPharmaceuticals, Inc., then a publicly traded, commercial-stage company. Previously at Aimmune Therapeutics, Inc., Mr. Ryali held roles of increasing responsibility, most recently as vice president of finance. Earlier in his career, he worked at Onyx Pharmaceuticals, Inc. and Amgen Inc. in finance-related positions of increasing responsibility. Mr. Ryali earned an MBA from the UCLA Anderson School of Management and a BA from the University of California, Los Angeles, with a double major in economics and microbiology, immunology, and molecular genetics.
“Caribou’s leadership in developing CRISPR genome-edited cell therapies and the current momentum across the pipeline continue to stand out in the biotech landscape,” said Mr. Ryali. “I look forward to working closely with teams across this mission-driven organization as we focus on delivering off-the-shelf CAR-T cell therapies to patients with devastating diseases who need readily available and more broadly accessible treatment options.”
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/8d7c3f3b-b81a-4d70-81b9-76bd2fe84c9f
About Caribou’s novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit www.cariboubio.com.
Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, without limitation, statements related to Caribou’s strategy, plans, and objectives, and expectations regarding its clinical and preclinical development programs. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include, without limitation, risks inherent in the development of cell therapy products; uncertainties related to the initiation, cost, timing, progress, and results of Caribou’s current and future research and development programs, preclinical studies, and clinical trials; and the risk that initial, preliminary, or interim clinical trial data will not ultimately be predictive of the safety and efficacy of Caribou’s product candidates or that clinical outcomes may differ as patient enrollment continues and as more patient data becomes available; the risk that preclinical study results observed will not be borne out in human patients or different conclusions or considerations are reached once additional data have been received and fully evaluated; the ability to obtain key regulatory input and approvals; as well as other risk factors described from time to time in Caribou’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent filings. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, Caribou undertakes no obligation to update publicly any forward-looking statements for any reason.
Caribou Biosciences, Inc. Contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com
Media:
Peggy Vorwald, PhD
media@cariboubio.com
FAQ
When did Sri Ryali join Caribou Biosciences (CRBU) as CFO?
How many clinical-stage programs is CRBU currently advancing?
What is Caribou Biosciences' (CRBU) main therapeutic focus?
What are Sri Ryali's previous work experiences before joining CRBU?
What key milestones does CRBU expect in 2025?
